1173897-87-4

Usage

Uses

Used in Pharmaceutical Industry:
(5-Bromo-4-methylthiazol-2-yl)methanol is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and functional groups enable the development of new drugs with different therapeutic properties, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
In the agrochemical industry, (5-Bromo-4-methylthiazol-2-yl)methanol is utilized as a key component in the synthesis of agrochemicals. Its chemical versatility allows for the creation of new compounds with potential applications in pest control, crop protection, and other agricultural areas.
Used in Organic Synthesis:
(5-Bromo-4-methylthiazol-2-yl)methanol serves as an important intermediate in organic synthesis, where it can be used to create a wide range of organic compounds with various applications. Its unique structure and functional groups make it a valuable asset in the development of new materials and chemicals.

Upstream product

• 13750-63-5 (4-methylthiazol-2-yl)-methanol 
• 13750-68-0 4-methyl-thiazole-2-carbaldehyde 

Downstream Products

• 1346817-08-0 3-[1-(5-fluoro-2-methoxyphenyl)ethoxy]-5-[5-(methylsulfonyl)-1,2,4-thiadiazol-3-yl]pyridin-2-amine 
• 1426668-69-0 6-(2-(hydroxymethyl)-4-methylthiazol-5-yl)-N-(2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1459695-60-3 C₁₅H₁₉NOS 
• 1459695-70-5 C₁₂H₁₀F₃NOS 
• 1459695-42-1 C₃₂H₃₂F₅N₃O₂S 
• 1459695-41-0 C₂₅H₂₉F₂N₃O₂S 
• 1459695-61-4 C₁₅H₁₈ClNS 
• 1459695-28-3 C₂₉H₃₅F₂N₃O₂S 
• 1459695-62-5 C₂₂H₂₂F₂N₂O₂S 
• 1459695-08-9 C₂₀H₂₀F₂N₄O₂S 
• 1459695-56-7 C₁₇H₁₃F₂N₃O₂S 
• 1459695-72-7 C₁₉H₁₃F₅N₂O₂S 
• 1459695-71-6 C₁₂H₉ClF₃NS 
• 1459695-50-1 C₂₆H₂₆F₅N₃O₂S 

Relevant academic research and scientific papers

Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists

G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders. During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)?=?75?nM, maximal response (Emax)?=?122%) starting from a high-throughput screening hit 3 (EC50?=?470?nM, Emax?=?56%). The structural features of a reported GPR52 agonist were applied to 3, led to design 4-azolylbenzamides as novel GPR52 agonists. A structure–activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole derivative 4u, which demonstrated excellent bioavailability in rats (F?=?53.8%). Oral administration of 4u (10?mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice. Thus, 4u is a promising lead compound for drug discovery research of GPR52 agonists.

ANTIMICROBIAL AGENTS

The invention provides compounds of formual (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.